Analysis of Clinical Factors and Mortality in Diffuse Large B-cell Lymphoma Patients Over or Under 80 Years of Age

Shinji Hasebe, Keiko Tanaka, Yoshihiro Miyake, Hiroaki Asai, Kazuto Takeuchi, Tomomi Fujii, Hitoshi Kawazoe, Kazushi Tanimoto, Jun Yamanouchi, Taichi Azuma, Masaki Yasukawa, Yoshihiro Yakushijin

研究成果: Article

抄録

Background: The prognosis of diffuse large B-cell lymphoma (DLBCL) is remarkably improved after R-CHOP therapy. However, there are few detailed reports regarding very elderly DLBCL patients. We investigated relationships between prognostic factors and mortality risk in DLBCL patients, especially those aged 80 years or more. Methods: The study subjects consisted of 141 patients newly-diagnosed with de novo DLBCL. Information regarding age, sex, stage, performance status (PS), lactate dehydrogenase (LDH), extranodal (EN) involvement, and therapies was available. Results: For the 141 patients, the female sex was significantly inversely related to mortality, whereas age ≥80 years, PS ≥2, and non-standard therapy were significantly positively associated with death. No associations were observed between death and stage, LDH, or EN. When classifying patients by age (<80 [n = 108] and ≥80 [n = 33] years), a significant inverse association between female sex and mortality was found only in the latter (very elderly) group. Positive relationships of PS ≥2 with mortality was more pronounced in patients ≥80 years of age than in those <80 years of age. A significant positive relationship with non-standard therapy was found only in patients <80 years of age. Conclusion: PS ≥2 may be positively associated with mortality, regardless of age. Female sex may be inversely related to mortality only in DLBCL patients aged 80 years or more, possibly due to the difference in rituximab clearance between the two study groups.

元の言語English
ジャーナルInternational Journal of Gerontology
DOI
出版物ステータスAccepted/In press - 2017 1 1
外部発表Yes

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Statistical Factor Analysis
Mortality
L-Lactate Dehydrogenase
Therapeutics

ASJC Scopus subject areas

  • Geriatrics and Gerontology

これを引用

Analysis of Clinical Factors and Mortality in Diffuse Large B-cell Lymphoma Patients Over or Under 80 Years of Age. / Hasebe, Shinji; Tanaka, Keiko; Miyake, Yoshihiro; Asai, Hiroaki; Takeuchi, Kazuto; Fujii, Tomomi; Kawazoe, Hitoshi; Tanimoto, Kazushi; Yamanouchi, Jun; Azuma, Taichi; Yasukawa, Masaki; Yakushijin, Yoshihiro.

:: International Journal of Gerontology, 01.01.2017.

研究成果: Article

Hasebe, S, Tanaka, K, Miyake, Y, Asai, H, Takeuchi, K, Fujii, T, Kawazoe, H, Tanimoto, K, Yamanouchi, J, Azuma, T, Yasukawa, M & Yakushijin, Y 2017, 'Analysis of Clinical Factors and Mortality in Diffuse Large B-cell Lymphoma Patients Over or Under 80 Years of Age', International Journal of Gerontology. https://doi.org/10.1016/j.ijge.2017.11.001
Hasebe, Shinji ; Tanaka, Keiko ; Miyake, Yoshihiro ; Asai, Hiroaki ; Takeuchi, Kazuto ; Fujii, Tomomi ; Kawazoe, Hitoshi ; Tanimoto, Kazushi ; Yamanouchi, Jun ; Azuma, Taichi ; Yasukawa, Masaki ; Yakushijin, Yoshihiro. / Analysis of Clinical Factors and Mortality in Diffuse Large B-cell Lymphoma Patients Over or Under 80 Years of Age. :: International Journal of Gerontology. 2017.
@article{fd5a6da19cae4de8b78d64cf8ebdcab0,
title = "Analysis of Clinical Factors and Mortality in Diffuse Large B-cell Lymphoma Patients Over or Under 80 Years of Age",
abstract = "Background: The prognosis of diffuse large B-cell lymphoma (DLBCL) is remarkably improved after R-CHOP therapy. However, there are few detailed reports regarding very elderly DLBCL patients. We investigated relationships between prognostic factors and mortality risk in DLBCL patients, especially those aged 80 years or more. Methods: The study subjects consisted of 141 patients newly-diagnosed with de novo DLBCL. Information regarding age, sex, stage, performance status (PS), lactate dehydrogenase (LDH), extranodal (EN) involvement, and therapies was available. Results: For the 141 patients, the female sex was significantly inversely related to mortality, whereas age ≥80 years, PS ≥2, and non-standard therapy were significantly positively associated with death. No associations were observed between death and stage, LDH, or EN. When classifying patients by age (<80 [n = 108] and ≥80 [n = 33] years), a significant inverse association between female sex and mortality was found only in the latter (very elderly) group. Positive relationships of PS ≥2 with mortality was more pronounced in patients ≥80 years of age than in those <80 years of age. A significant positive relationship with non-standard therapy was found only in patients <80 years of age. Conclusion: PS ≥2 may be positively associated with mortality, regardless of age. Female sex may be inversely related to mortality only in DLBCL patients aged 80 years or more, possibly due to the difference in rituximab clearance between the two study groups.",
keywords = "Diffuse large B-cell lymphoma, Mortality, Prognostic factors, Rituximab clearance",
author = "Shinji Hasebe and Keiko Tanaka and Yoshihiro Miyake and Hiroaki Asai and Kazuto Takeuchi and Tomomi Fujii and Hitoshi Kawazoe and Kazushi Tanimoto and Jun Yamanouchi and Taichi Azuma and Masaki Yasukawa and Yoshihiro Yakushijin",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.ijge.2017.11.001",
language = "English",
journal = "International Journal of Gerontology",
issn = "1873-9598",
publisher = "Elsevier Taiwan LLC",

}

TY - JOUR

T1 - Analysis of Clinical Factors and Mortality in Diffuse Large B-cell Lymphoma Patients Over or Under 80 Years of Age

AU - Hasebe, Shinji

AU - Tanaka, Keiko

AU - Miyake, Yoshihiro

AU - Asai, Hiroaki

AU - Takeuchi, Kazuto

AU - Fujii, Tomomi

AU - Kawazoe, Hitoshi

AU - Tanimoto, Kazushi

AU - Yamanouchi, Jun

AU - Azuma, Taichi

AU - Yasukawa, Masaki

AU - Yakushijin, Yoshihiro

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: The prognosis of diffuse large B-cell lymphoma (DLBCL) is remarkably improved after R-CHOP therapy. However, there are few detailed reports regarding very elderly DLBCL patients. We investigated relationships between prognostic factors and mortality risk in DLBCL patients, especially those aged 80 years or more. Methods: The study subjects consisted of 141 patients newly-diagnosed with de novo DLBCL. Information regarding age, sex, stage, performance status (PS), lactate dehydrogenase (LDH), extranodal (EN) involvement, and therapies was available. Results: For the 141 patients, the female sex was significantly inversely related to mortality, whereas age ≥80 years, PS ≥2, and non-standard therapy were significantly positively associated with death. No associations were observed between death and stage, LDH, or EN. When classifying patients by age (<80 [n = 108] and ≥80 [n = 33] years), a significant inverse association between female sex and mortality was found only in the latter (very elderly) group. Positive relationships of PS ≥2 with mortality was more pronounced in patients ≥80 years of age than in those <80 years of age. A significant positive relationship with non-standard therapy was found only in patients <80 years of age. Conclusion: PS ≥2 may be positively associated with mortality, regardless of age. Female sex may be inversely related to mortality only in DLBCL patients aged 80 years or more, possibly due to the difference in rituximab clearance between the two study groups.

AB - Background: The prognosis of diffuse large B-cell lymphoma (DLBCL) is remarkably improved after R-CHOP therapy. However, there are few detailed reports regarding very elderly DLBCL patients. We investigated relationships between prognostic factors and mortality risk in DLBCL patients, especially those aged 80 years or more. Methods: The study subjects consisted of 141 patients newly-diagnosed with de novo DLBCL. Information regarding age, sex, stage, performance status (PS), lactate dehydrogenase (LDH), extranodal (EN) involvement, and therapies was available. Results: For the 141 patients, the female sex was significantly inversely related to mortality, whereas age ≥80 years, PS ≥2, and non-standard therapy were significantly positively associated with death. No associations were observed between death and stage, LDH, or EN. When classifying patients by age (<80 [n = 108] and ≥80 [n = 33] years), a significant inverse association between female sex and mortality was found only in the latter (very elderly) group. Positive relationships of PS ≥2 with mortality was more pronounced in patients ≥80 years of age than in those <80 years of age. A significant positive relationship with non-standard therapy was found only in patients <80 years of age. Conclusion: PS ≥2 may be positively associated with mortality, regardless of age. Female sex may be inversely related to mortality only in DLBCL patients aged 80 years or more, possibly due to the difference in rituximab clearance between the two study groups.

KW - Diffuse large B-cell lymphoma

KW - Mortality

KW - Prognostic factors

KW - Rituximab clearance

UR - http://www.scopus.com/inward/record.url?scp=85039058747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039058747&partnerID=8YFLogxK

U2 - 10.1016/j.ijge.2017.11.001

DO - 10.1016/j.ijge.2017.11.001

M3 - Article

AN - SCOPUS:85039058747

JO - International Journal of Gerontology

JF - International Journal of Gerontology

SN - 1873-9598

ER -